Skip to Content

Dexrazoxane Injection

Last Updated: July 13, 2017
Status: Current

Dexrazoxane Injection

Products Affected - Description
  • Totect kit, Biocodex USA
    500 mg, vial, (only for extravasation injuries) 10 count (NDC 38423-0110-01)

 
Zinecard injection, Pfizer
250 mg, vial, 1 count (NDC 00013-8717-62)
500 mg, vial, 1 count (NDC 00013-8727-89)
 
Dexrazoxane injection, Mylan Institutional
250 mg, vial, 1 count (NDC 67457-0207-25)
500 mg, vial, 1 count (NDC 67457-0208-50)
Reason for the Shortage
    • Biocodex USA acquired Totect from Apricus Pharmaceuticals in April 2013.
    • West-Ward is not actively marketing dexrazoxane injection at this time.
    • Mylan did not provide a reason for the back order.
    • Pfizer states manufacturing delay as the reason for the back order.
Available Products
  • There are no presentations available.

Estimated Resupply Dates

    • Biocodex USA has not yet started manufacturing Totect and the company cannot estimate when product will be available.
    • Pfizer has Zinecard 250 mg and 500 mg vials on back order and the company estimates a release date of October-November 2017 for the 250 mg vials and 3rd quarter 2018 for the 500 mg vials.
    • Mylan has dexrazoxane 250 mg and 500 mg vials on back order and the company cannot estimate a release date.

Updated

July 13 and 3, January 11, 2017; October 21, July 26, 15 and 7, June 22 and 2, March 23, February 25 and 2, 2016; October 29, August 26 and 5, July 1, May 14, March 9, January 21, 2015; November 20, October 13, August 8, June 2, April 3, 2014; December 23, October 28, September 23, August 29 and 6, July 25 and 15, May 28, April 17, February 26 and 22, 2013; December 17, November 30, September 14, July 26, June 5, May 25, April 17, March 8, January 13 and 11, 2012; December 15, November 30, 2011, University of Utah, Drug Information Service. Copyright 2017, Drug Information Service, University of Utah, Salt Lake City, UT.

Hide